Can targeting the CB1 receptor treat obesity? A review of past failures and new approaches
A review of CB1 receptor drugs for obesity found that while rimonabant was effective but unsafe, newer approaches including peripheral-only blockers and neutral antagonists may retain weight-loss benefits without psychiatric side effects.
Quick Facts
What This Study Found
Rimonabant (CB1 inverse agonist) effectively produced weight loss but was withdrawn due to depression and suicidal ideation. An inverse relationship between cannabis use and BMI has been confirmed by multiple groups. Newer preclinical approaches, including peripheral-only CB1 blockers and neutral antagonists, may retain therapeutic potential for obesity without brain-related side effects.
Key Numbers
Rimonabant was effective for weight loss but withdrawn for psychiatric side effects; inverse cannabis use-BMI relationship confirmed by multiple studies; peripheral-only CB1 approaches in development.
How They Did This
Narrative review of preclinical and clinical studies on CB1 receptor ligands (inverse agonists, agonists, partial agonists, neutral antagonists) and their effects on body weight.
Why This Research Matters
Obesity rates are rising globally and treatment options are limited. The CB1 receptor remains one of the most promising therapeutic targets, but the rimonabant experience showed that brain-penetrant CB1 blockers are too risky.
The Bigger Picture
The paradox that chronic cannabis use is associated with lower BMI, despite THC acutely stimulating appetite, points to complex regulatory mechanisms in the endocannabinoid system that could be harnessed therapeutically.
What This Study Doesn't Tell Us
Narrative review; most novel approaches are preclinical only; the cannabis use-BMI paradox has multiple possible explanations beyond CB1 effects; translating peripheral-only CB1 blockers to humans remains unproven.
Questions This Raises
- ?Will peripheral-only CB1 blockers work in human obesity trials?
- ?Does the cannabis-BMI association hold across all populations and use patterns?
Trust & Context
- Key Stat:
- Cannabis use inversely associated with BMI; new CB1 approaches aim to avoid psychiatric risks
- Evidence Grade:
- Moderate: synthesizes extensive preclinical and clinical literature but newer approaches remain unproven in humans.
- Study Age:
- Published 2020.
- Original Title:
- Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.
- Published In:
- Biomolecules, 10(6) (2020)
- Authors:
- Murphy, Thomas, Le Foll, Bernard(40)
- Database ID:
- RTHC-02737
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can the endocannabinoid system be targeted for weight loss?
Yes. The CB1 receptor was proven effective for weight loss (rimonabant), but brain-penetrant blockers caused psychiatric side effects. Peripheral-only approaches may retain benefits without risks.
Why are cannabis users often thinner despite getting "the munchies"?
The acute appetite stimulation from THC is well-known, but chronic cannabis use is paradoxically associated with lower BMI. This may involve complex receptor adaptations that could inform obesity treatment.
Read More on RethinkTHC
- cannabis-cardiovascular-heart-risk-stroke
- cannabis-heart-cardiovascular-risk
- coughing-up-stuff-after-quitting-weed
- lung-recovery-after-quitting-smoking-weed
- lung-recovery-quitting-weed
- quitting-weed-female-hormones
- quitting-weed-weight-gain-loss-diet-appetite
- sex-after-quitting-weed
- weed-DUI-driving-impaired-cannabis-laws
- weed-acne-skin
- weed-fertility-sperm
- weed-gut-digestion-problems
- weed-heart-health
- weed-testosterone-levels
Cite This Study
https://rethinkthc.com/research/RTHC-02737APA
Murphy, Thomas; Le Foll, Bernard. (2020). Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.. Biomolecules, 10(6). https://doi.org/10.3390/biom10060855
MLA
Murphy, Thomas, et al. "Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.." Biomolecules, 2020. https://doi.org/10.3390/biom10060855
RethinkTHC
RethinkTHC Research Database. "Targeting the Endocannabinoid CB1 Receptor to Treat Body Wei..." RTHC-02737. Retrieved from https://rethinkthc.com/research/murphy-2020-targeting-the-endocannabinoid-cb1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.